Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the United States. The company has market cap of $1.22 billion. The Company’s product candidates include tazemetostat, an inhibitor of the EZH2 HMT, which is in five-arm Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma ; Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II and Ib clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial for elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function, as well as Phase II clinical trial in adult patients with ovarian cancer. It currently has negative earnings. The firm is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL.
Axa decreased Flex Ltd (FLEX) stake by 92.33% reported in 2017Q3 SEC filing. Axa sold 140,400 shares as Flex Ltd (FLEX)’s stock rose 0.43%. The Axa holds 11,668 shares with $193,000 value, down from 152,068 last quarter. Flex Ltd now has $9.48B valuation. The stock increased 1.70% or $0.3 during the last trading session, reaching $17.96. About 2.18 million shares traded. Flex Ltd. (NASDAQ:FLEX) has risen 35.11% since February 24, 2017 and is uptrending. It has outperformed by 18.41% the S&P500.
Investors sentiment decreased to 0.92 in Q3 2017. Its down 0.27, from 1.19 in 2017Q2. It turned negative, as 33 investors sold FLEX shares while 106 reduced holdings. 38 funds opened positions while 90 raised stakes. 497.19 million shares or 0.70% less from 500.69 million shares in 2017Q2 were reported. Lord Abbett & Ltd Liability Com holds 0.06% or 1.21 million shares. Creative Planning reported 144,167 shares. First Eagle Inv Management Ltd Liability has invested 0.12% of its portfolio in Flex Ltd. (NASDAQ:FLEX). Moreover, Clarivest Asset Mngmt Ltd Liability Corporation has 0.01% invested in Flex Ltd. (NASDAQ:FLEX) for 22,100 shares. Towle Com has 2.04 million shares. Raymond James Finance Service Inc invested 0% in Flex Ltd. (NASDAQ:FLEX). Clifford Swan Investment Counsel Ltd Com holds 0.16% or 155,699 shares in its portfolio. Shine Investment Advisory Svcs Incorporated reported 2,886 shares. Robeco Institutional Asset Mgmt Bv owns 212,530 shares. Ardsley Advisory Prtn owns 28,000 shares for 0.06% of their portfolio. Westpac holds 0.01% or 34,555 shares. Panagora Asset Mngmt has 0.03% invested in Flex Ltd. (NASDAQ:FLEX) for 457,163 shares. Kbc Grp Nv reported 225,357 shares or 0.03% of all its holdings. Peak6 Invests Limited Partnership reported 15,406 shares. Moreover, Oregon Employees Retirement Fund has 0.03% invested in Flex Ltd. (NASDAQ:FLEX).
Among 15 analysts covering Flextronics International Ltd. (NASDAQ:FLEX), 11 have Buy rating, 1 Sell and 3 Hold. Therefore 73% are positive. Flextronics International Ltd. had 48 analyst reports since July 28, 2015 according to SRatingsIntel. The firm has “Sell” rating by Zacks given on Friday, August 21. The company was upgraded on Tuesday, August 11 by Zacks. The stock of Flex Ltd. (NASDAQ:FLEX) has “Buy” rating given on Tuesday, September 20 by Goldman Sachs. The company was maintained on Wednesday, January 3 by RBC Capital Markets. Needham maintained Flex Ltd. (NASDAQ:FLEX) rating on Tuesday, October 20. Needham has “Buy” rating and $14 target. The stock of Flex Ltd. (NASDAQ:FLEX) earned “Buy” rating by Goldman Sachs on Wednesday, October 5. RBC Capital Markets maintained the shares of FLEX in report on Monday, October 5 with “Outperform” rating. The company was maintained on Thursday, May 12 by Bank of America. The rating was maintained by RBC Capital Markets on Wednesday, August 30 with “Buy”. The rating was upgraded by Citigroup to “Buy” on Friday, December 11.
Analysts await Flex Ltd. (NASDAQ:FLEX) to report earnings on April, 26. They expect $0.23 EPS, down 11.54% or $0.03 from last year’s $0.26 per share. FLEX’s profit will be $121.36 million for 19.52 P/E if the $0.23 EPS becomes a reality. After $0.22 actual EPS reported by Flex Ltd. for the previous quarter, Wall Street now forecasts 4.55% EPS growth.
Since February 1, 2018, it had 0 insider purchases, and 1 insider sale for $243,573 activity. 13,597 Flex Ltd. (NASDAQ:FLEX) shares with value of $243,573 were sold by SHIH WILLY C.
Axa increased Ultra Clean Hldgs Inc (NASDAQ:UCTT) stake by 16,200 shares to 137,200 valued at $4.20M in 2017Q3. It also upped Roper Technologies Inc (NYSE:ROP) stake by 17,182 shares and now owns 401,876 shares. Caci Intl Inc (NYSE:CACI) was raised too.
Foresite Capital Management Ii Llc holds 11.92% of its portfolio in Epizyme, Inc. for 1.54 million shares. Palo Alto Investors Llc owns 6.40 million shares or 5.13% of their US portfolio. Moreover, Nea Management Company Llc has 4.31% invested in the company for 6.46 million shares. The Maryland-based Rock Springs Capital Management Lp has invested 1.19% in the stock. Oracle Investment Management Inc, a Connecticut-based fund reported 369,403 shares.
Since January 1, 0001, it had 1 insider purchase, and 3 insider sales for $1.35 million activity.
Analysts await Epizyme, Inc. (NASDAQ:EPZM) to report earnings on March, 8. They expect $-0.56 EPS, up 6.67% or $0.04 from last year’s $-0.6 per share. After $-0.63 actual EPS reported by Epizyme, Inc. for the previous quarter, Wall Street now forecasts -11.11% EPS growth.